LeMaitre Vascular (NASDAQ:LMAT) Upgraded at StockNews.com

StockNews.com upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a hold rating to a buy rating in a research report released on Monday.

A number of other equities research analysts have also issued reports on LMAT. Barrington Research increased their target price on shares of LeMaitre Vascular from $79.00 to $92.00 and gave the stock an outperform rating in a report on Friday, August 2nd. Roth Capital upgraded shares of LeMaitre Vascular to a strong-buy rating in a report on Friday, May 31st. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They set a buy rating and a $105.00 target price on the stock. Roth Mkm reissued a buy rating and issued a $100.00 price objective on shares of LeMaitre Vascular in a research report on Friday, May 31st. Finally, Stifel Nicolaus raised shares of LeMaitre Vascular from a hold rating to a buy rating and increased their price objective for the company from $59.00 to $75.00 in a research report on Friday, April 26th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, LeMaitre Vascular has an average rating of Buy and an average target price of $86.50.

LeMaitre Vascular Price Performance

NASDAQ:LMAT opened at $82.05 on Monday. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 54.34, a PEG ratio of 2.63 and a beta of 0.89. The company’s 50-day moving average is $83.17 and its two-hundred day moving average is $73.15. LeMaitre Vascular has a 1-year low of $44.27 and a 1-year high of $91.76.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.63%. The company had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. During the same period in the previous year, the business posted $0.37 EPS. LeMaitre Vascular’s revenue was up 11.4% on a year-over-year basis. As a group, equities analysts anticipate that LeMaitre Vascular will post 1.77 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, August 29th. Investors of record on Thursday, August 15th will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.78%. The ex-dividend date is Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is 42.38%.

Insider Activity at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction on Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the transaction, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction on Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the sale, the chief executive officer now owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 12,976 shares of the stock in a transaction on Friday, July 12th. The stock was sold at an average price of $86.07, for a total transaction of $1,116,844.32. Following the sale, the chief executive officer now owns 1,985,358 shares of the company’s stock, valued at approximately $170,879,763.06. The disclosure for this sale can be found here. Insiders have sold 40,188 shares of company stock valued at $3,463,614 in the last ninety days. Insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

A number of large investors have recently bought and sold shares of LMAT. YHB Investment Advisors Inc. acquired a new stake in LeMaitre Vascular during the 1st quarter worth $36,000. SRS Capital Advisors Inc. boosted its stake in LeMaitre Vascular by 325.5% during the 4th quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 524 shares during the period. GAMMA Investing LLC boosted its stake in LeMaitre Vascular by 57.0% during the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 199 shares during the period. West Oak Capital LLC acquired a new stake in LeMaitre Vascular during the 2nd quarter worth $58,000. Finally, nVerses Capital LLC lifted its stake in shares of LeMaitre Vascular by 33.3% in the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after acquiring an additional 200 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.